95.47
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $95.47, with a volume of 27.72M.
It is down -6.00% in the last 24 hours and down -13.17% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$101.56
Open:
$97.13
24h Volume:
27.72M
Relative Volume:
2.34
Market Cap:
$165.90B
Revenue:
$44.33B
Net Income/Loss:
$6.50B
P/E Ratio:
25.68
EPS:
3.717
Net Cash Flow:
$7.40B
1W Performance:
-7.06%
1M Performance:
-13.17%
6M Performance:
-25.20%
1Y Performance:
-26.39%
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
ABT
Abbott Laboratories
|
95.47 | 176.48B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
338.38 | 130.69B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
85.65 | 111.83B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
63.42 | 96.02B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
79.05 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories (ABT) Q1 2026 Earnings Call Highlights: Strong Medical Devices Growth Amid ... By GuruFocus - Investing.com Canada
Inside Biotech: Abbott’s solid quarter isn’t enough as $21B bet rattles investors - Proactive financial news
Flu Season Fades, Abbott Stumbles: Is the 54-Year Dividend King Still Worth the Crown? - NAI500
New cancer diagnostics and product updates see Abbott Laboratories stock fall amid oversold technicals - Traders Union
Why Abbott Laboratories Stock Tumbled on Thursday - The Motley Fool
Abbott Laboratories Bets on Devices in 2026 Call - TipRanks
Why Abbott Laboratories Stock Tumbled on Thursday - The Motley Fool
Abbott Laboratories (ABT) Lowers Earnings Outlook Amid Acquisiti - GuruFocus
Abbott Laboratories (ABT) Shares Fall 6.0% -- What GF Score of 8 - GuruFocus
Is Abbott Laboratories (ABT) Now Offering Value After A 20% Share Price Slide? - simplywall.st
Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix - WSJ
Abbott stock tumbles on earnings. Nutrition business is struggling and merger costs biting. - MSN
Abbott Laboratories Slammed On Its Post-Exact Sciences Guidance - Investor's Business Daily
These Stocks Are Today’s Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More - Barron's
Abbott trims 2026 profit forecast on Exact deal hit, shares fall - Reuters
Abbott Laboratories (ABT) Reports Q1 2026 Earnings with Mixed Re - GuruFocus
Abbott Laboratories (ABT) Reports Q1 2026 Earnings, Adjusts Fore - GuruFocus
Abbott Laboratories (ABT) Faces Investor Concerns After Earnings Update - GuruFocus
Abbott stock slips on guidance cut, ranks 10th in healthcare equipment Quant ratings (ABT:NYSE) - Seeking Alpha
Abbott cuts profit forecast in wake of Exact Sciences deal - Modern Healthcare
Abbott Stock Falls Despite Q1 Earnings & Revenue Beat - Yahoo Finance
Abbott Laboratories: This Dividend Growth King Has Rarely Been So Cheap (NYSE:ABT) - Seeking Alpha
Stocks making the biggest moves midday: Abbott Labs, AMD, Charles Schwab, On Semi & more - CNBC
Leerink reiterates Abbott Labs stock rating at Market Perform By Investing.com - Investing.com India
Abbott Laboratories Q1 2026 Earnings Call Summary - Yahoo Finance
Abbott Laboratories (ABT) Reports Q1 Earnings In-Line with Expec - GuruFocus
Abbott cuts earnings outlook to reflect Exact Sciences buyout - MSN
Abbott lowers earnings forecast after $21B Exact Sciences buy - MedTech Dive
Health Care ETFs take notice as Abbott Laboratories slides on earnings - Seeking Alpha
Abbott Labs Reports Strong Q1 but Lowers EPS Guidance for 2026 - GuruFocus
Abbott Laboratories (ABL.DE) Drops 4.7% on XETRA After Earnings - Meyka
Abbott defeats lawsuit alleging Similac contaminated by heavy metals - Reuters
ABBV: Abbott Laboratories Reports In-Line EPS and Strong Revenue Beat - GuruFocus
Abbott Laboratories (ABT) Forecasts Neutral FX Impact on Q2 Reve - GuruFocus
Abbott (ABT) Maintains Revenue Growth Outlook Amidst Adjustments - GuruFocus
Abbott Laboratories (NYSE:ABT) Hits New 12-Month LowShould You Sell? - MarketBeat
Abbott (ABT.US) 1Q Adjusted EPS Beats; Nutrition Business Remains Weak - AASTOCKS.com
Abbott (ABT) Q1 2026 Earnings Call Transcript - The Motley Fool
Abbott Laboratories Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales - WSJ
Abbott Laboratories Q1 Earnings Call Highlights - MarketBeat
Abbott cuts profit forecast in wake of cancer screening deal - Crain's Chicago Business
Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag - Proactive financial news
Earnings call transcript: Abbott Labs Q1 2026 results align with expectations - Investing.com India
Abbott Laboratories (ABT) Lowers Earnings Outlook Despite Revenue Growth - GuruFocus
Abbott Earnings Beat Estimates. Why the Stock Is Slumping. - Barron's
Market movers: Hims & Hers, Abbott Laboratories, QVC… - Proactive financial news
Transcript: Abbott Laboratories Q1 2026 Earnings Conference CallAbbott Laboratories (NYSE:ABT) - Benzinga
Abbott Cuts 2026 Earnings Outlook Following First-Quarter Beat - marketscreener.com
Abbott Cuts Profit Forecast in Wake of Cancer Screening Deal - Bloomberg.com
Abbott Laboratories Stock (ABT) Opened Down by 4.34% on Apr 16: What Investors Need To Know - TradingKey
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):